Li, D., Chawla, N. S., Teague, A. S., Iizuka, K., Tang, H., Kapoor, V. N., Cheung, E. (2025). A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and/or locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4217